Dr. Daniel F. Mandri, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 43
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
FL license ME34257
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Doctors Hospital Coral Gables, FL
Medical groups
- Citrus Health Network, Inc. (49 clinicians)
- Florida Bay Associates LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 43
- Services billed
- 50
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 52 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $190 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $73.24 |
|---|---|
| Janssen Scientific Affairs, LLC | $42.35 |
| AbbVie Inc. | $28.60 |
| Neurocrine Biosciences, Inc. | $25.20 |
| Vanda Pharmaceuticals Inc. | $20.25 |
| Food and Beverage | $190 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $1,013,726 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
AbbVie Inc. · Terminated · NCT05443724 - ITI-1284-101
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - ITI-1284-201
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363 - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT07011745 - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.